Moderna, Inc.
26.3.2024 12:03:57 CET | ACCESS Newswire | Press release
- mRNA-1283 induced a more robust immune response compared to Spikevax® COVID-19 vaccine, mRNA-1273.222
- Next-generation mRNA vaccine design offers the potential of longer shelf life and storage advantages, and paves the way for combination vaccine against influenza and COVID-19, mRNA-1083
CAMBRIDGE, MA / ACCESSWIRE / March 26, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that mRNA-1283, the Company's next-generation COVID-19 vaccine, has successfully met the primary endpoints of its Phase 3 clinical trial, demonstrating a higher immune response against SARS-CoV-2 when compared to mRNA-1273.222, Moderna's licensed COVID-19 vaccine.
"We are excited to announce our fourth infectious disease vaccine program with positive Phase 3 data, further validating our robust mRNA platform," said Stéphane Bancel, Chief Executive Officer of Moderna. "mRNA-1283 is a critical component of our combination vaccine against flu and COVID-19, mRNA-1083, and this milestone gives us confidence in our ability to bring this much needed vaccine to market."
In the NextCOVE (NCT05815498) Phase 3 pivotal trial, mRNA-1283 was shown to elicit a higher immune response against both the Omicron BA.4/BA.5 and original virus strains of SARS-CoV-2, compared to mRNA-1273.222. Importantly, this benefit was most acutely seen in participants over the age of 65 years, the population that remains at highest risk for severe outcomes from COVID-19. The most common solicited local adverse event was injection site pain. The most common solicited systemic adverse events included headache, fatigue, myalgia and chills.
The NEXTCove clinical trial is a randomized, observer-blind, active-controlled study of approximately 11,400 individuals aged 12 years and older in the United States, United Kingdom and Canada. mRNA-1283 was found to have a similar safety profile to Moderna's approved COVID-19 vaccines.
The storage, shelf life and pre-filled syringe presentation of mRNA-1283 could alleviate healthcare provider burden and potentially increase access into new settings to serve public health. A detailed analysis of the Phase 3 clinical trial data for mRNA-1283 will be shared at the Company's Vaccines Day event on March 27 and presented at upcoming scientific conferences.
About Moderna
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna's mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Spikevax® is a registered trademark of Moderna.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: the potential longer refrigerator shelf life and storage advantages of mRNA-1283 compared to Spikevax; and the ability of mRNA-1283 to maintain effectiveness compared to Spikevax. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this press release.
Moderna Contacts
Media:
Elise Meyer
Sr. Director, Corporate Communications
+1 617-852-7041
Elise.Meyer@modernatx.com
Investors:
Lavina Talukdar
Senior Vice President & Head of Investor Relations
+1 617-209-5834
Lavina.Talukdar@modernatx.com
SOURCE: Moderna, Inc.
View the original press release on accesswire.com
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Valsoft's TAG Software Group Enters the Content Operations Market with the Acquisition of Chalco6.11.2026 16:25:00 CET | Press release
MONTRÉAL, QC / ACCESS Newswire / November 6, 2026 / Valsoft Corporation Inc. ("Valsoft"), a Canadian company specializing in the acquisition and long-term development of vertical market software businesses, today announced the acquisition of 100% of Chalco, a software platform for managing the full lifecycle of product content and information, from Hyphen-Group. The deal marks Valsoft's entry into the content operations market, a fast-growing space that is increasingly critical to organizational growth in the age of AI, and brings the number of industries in which Valsoft operates to more than 20. The acquisition was completed by TAG Software Group through Chalco Technologies Srl ("Chalco Technologies"), a newly formed company wholly owned by Valsoft. Chalco was developed within Hyphen-Group, an Italian company active in the content operations market for more than 25 years, with offices in Affi (Verona), Milan, and Lugano, Switzerland, and a client base that includes some of the world'
Innodata Reports Record Third Quarter 2026 Results5.11.2026 22:05:00 CET | Press release
NEW YORK, NY / ACCESS Newswire / November 5, 2026 / INNODATA INC. (Nasdaq:INOD) today reported results for the third quarter ended September 30, 2026.Revenue of $95.6 million, representing 53% year-over-year revenue growth.Adjusted Gross Profit of $38.3 million, representing Adjusted Gross Margin of 40%.*Adjusted EBITDA of $17.7 million, or 18.5% of revenue, an increase of $1.5 million from $16.2 million in the same period last year.*Net income of $10.3 million, or $0.30 per basic share and $0.29 per diluted share for the three-month period ended September 30, 2026, compared to net income of $8.3 million, or $0.26 per basic share and $0.24 per diluted share, in the same period last year.Cash and cash equivalents of $164.0 million as of September 30, 2026, an increase of $81.7 million from $82.2 million as of December 31, 2025. Cash as of September 30, 2026 includes customer prepayments related to pass-through costs; net of these prepayments, cash was approximately $153.7 million as of
MicroVision and LAKE FUSION Technologies Sign Multi-Year Strategic Partnership Agreement for IRIS(TM) Lidar Sensors5.11.2026 15:20:00 CET | Press release
ORLANDO, FL AND MARKDORF, GERMANY / ACCESS Newswire / November 5, 2026 / MicroVision, Inc. (NASDAQ:MVIS), a leader in advanced perception solutions for industrial, security and defense, intelligent infrastructure, and automotive mobility, today announced a multi-year strategic partnership agreement with LAKE FUSION Technologies (LFT), a German developer of advanced sensor fusion and situational awareness systems. Under the agreement, LFT has committed to purchasing MicroVision IRIS™ long-range lidar sensors throughout 2027 and into 2028 for integration into its Awareness Systems (AS-1), designed to enhance safety and obstacle detection for civil and military helicopter operations. The multi-year agreement marks another significant commercial milestone following the companies' June 2026 announcement to expedite the integration of IRIS lidar technology and accelerate the deployment of advanced situational awareness solutions. With testing and evaluation progressing into a formal strategi
Chervon Names Doug Palmer Vice President of Finance - Canada5.11.2026 15:00:00 CET | Press release
TORONTO, ON / ACCESS Newswire / November 5, 2026 / Effective November 9, 2026, Chervon names Doug Palmer Vice President of Finance - Canada, reporting to Neil Harrison, Vice President and Managing Director of Chervon Canada. He will also have a dotted-line reporting relationship to Ryan Wang, Chief Financial Officer, Chervon NA. Palmer brings to Chervon an exceptional 20-year career of increasingly responsible positions in Canadian financial management. During his 18-year career at J.M. Smucker, he held financial management positions as Analyst, Senior Manager, Director, and Senior Director, responsible for all elements of financial control and FP&A. Most recently, he served as Vice President of Finance at the Crump Group. "We have identified Canada as a strategic priority for Chervon with massive growth potential," said Joe Galli, Chervon CEO. "We are building the best leadership team in the Power Tool and OPE industry in Canada. Doug Palmer is an outstanding addition to this high-per
New EuroFinance Study, Sponsored by TIS, Puts Treasury at the Center of Cybersecurity5.11.2026 15:00:00 CET | Press release
BERLIN, DE / ACCESS Newswire / November 5, 2026 / New Deep Dive research, Cyber Risk Management: No Longer Just an IT Problem, finds that cyber risk is increasingly disrupting payments, liquidity management, and business continuity. Sponsored by TIS, a global leader in payments and cash management technology, the new report extracts insights from treasury and cybersecurity professionals across housing, commodities, manufacturing, consumer goods, and telecommunications who agree that cybersecurity is a growing treasury and liquidity risk. Why Treasury Is at the Center of Cyber Risk The ongoing digitization of the treasury ecosystem through APIs, cloud platforms, and automation has increased the speed and efficiency of treasury operations. While treasury teams are moving faster, their exposure to sophisticated cyber threats, including deepfake videos, fraudulent invoices, and manipulating approvals through compromised digital channels, has expanded in proportion. These threats most frequ
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom